Agenus (AGEN) Scheduled to Post Earnings on Tuesday

Agenus (NASDAQ:AGEN) is set to issue its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($3.10) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The business had revenue of $83.80 million during the quarter, compared to analysts’ expectations of $54.21 million. On average, analysts expect Agenus to post $-8 EPS for the current fiscal year and $-14 EPS for the next fiscal year.

Agenus Trading Down 8.2 %

AGEN stock traded down $1.04 during trading hours on Tuesday, hitting $11.72. 685,006 shares of the stock were exchanged, compared to its average volume of 688,571. The firm has a market capitalization of $245.53 million, a P/E ratio of -0.84 and a beta of 1.26. The company has a 50-day simple moving average of $10.93 and a two-hundred day simple moving average of $13.57. Agenus has a 12 month low of $4.78 and a 12 month high of $42.60.

Insider Activity at Agenus

In other Agenus news, insider Garo H. Armen acquired 25,000 shares of Agenus stock in a transaction that occurred on Thursday, February 15th. The shares were acquired at an average cost of $13.00 per share, with a total value of $325,000.00. Following the completion of the purchase, the insider now directly owns 31,298 shares of the company’s stock, valued at approximately $406,874. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.80% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $160.00 price objective on shares of Agenus in a research report on Thursday, March 14th. StockNews.com began coverage on Agenus in a report on Wednesday, April 17th. They set a “hold” rating on the stock. Finally, B. Riley reduced their price objective on Agenus from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, March 18th.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.